Norspan (Buprenorphine)

Buprenorphine delivered via the Norspan patch acts on opioid receptors to relieve pain in several chronic pain conditions.

• Chronic non‑cancer pain: Provides continuous analgesia to reduce baseline pain intensity.
• Cancer‑related pain: Controls persistent pain associated with malignant disease and its treatment.
• Severe breakthrough pain: Offers supplemental relief when baseline analgesia is insufficient.

• Buprenorphine is a high‑affinity partial agonist at the μ‑opioid receptor and an antagonist at the κ‑opioid receptor. By binding to μ‑receptors it produces analgesia while limiting maximal opioid effect, and κ‑antagonism may reduce dysphoria. The transdermal system releases the drug steadily through the skin, maintaining stable plasma concentrations that provide long‑lasting pain control. Steady delivery avoids peaks and troughs, improving tolerability and reducing the risk of withdrawal.

The Norspan transdermal patch may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Application site erythema: Redness or irritation at the patch site.
• Nausea: Feeling of sickness or urge to vomit.
• Constipation: Decreased bowel movements or difficulty passing stool.
• Dizziness: Light‑headed sensation, especially when standing.

Serious or Rare Side Effects

• Respiratory depression: Marked reduction in breathing rate, potentially life‑threatening.
• Severe hypotension: Significant drop in blood pressure causing faintness.
• Allergic reaction: Rash, swelling, or anaphylaxis requiring immediate medical attention.

When prescribing Norspan, clinicians should consider several safety measures to minimize risks.

• Patient selection: Assess opioid tolerance and history of substance abuse before initiating therapy.
• Concomitant CNS depressants: Avoid or closely monitor use with benzodiazepines, alcohol, or other sedatives.
• Respiratory function: Evaluate baseline respiratory status and monitor for signs of depression.
• Skin integrity: Inspect the application site regularly for irritation or allergic response.
• Pregnancy and lactation: Use only if potential benefit justifies potential risk; consult obstetric guidance.
• Store at room temperature: Keep patches below 30 °C in the original packaging, protected from light and moisture.

Buprenorphine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Full opioid agonists: Co‑administration may precipitate severe respiratory depression.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): Can increase buprenorphine plasma levels, raising toxicity risk.
• CNS depressants (e.g., barbiturates, high‑dose benzodiazepines): Heighten sedation and respiratory suppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce buprenorphine concentrations, diminishing analgesia.
• MAO inhibitors: Potential for additive opioid effects; monitor for enhanced sedation.
• Anticholinergic agents: May exacerbate constipation; observe bowel function.